TLDR
- ARK Invest liquidated $26.65M worth of Robinhood stock following the fintech company’s announcement of a 10% headcount reduction that drove shares higher
- Approximately $77M in Roku holdings were sold by ARK across several funds after Fox revealed plans to acquire the streaming platform for $22 billion at $160/share
- ARK purchased $46.18M in Eli Lilly stock during a price dip, coinciding with Lilly’s strategic purchase of neuroscience specialist 4E Therapeutics
- Coinbase received $18.92M in fresh investment from ARK as the crypto exchange expands into tokenized equities and AI-powered investment platforms
- Tesla maintains its position as ARK Innovation ETF’s top holding at 9.50%, while SpaceX has entered the fund’s top five assets
On June 18, Cathie Wood’s ARK Invest executed a strategic portfolio rebalancing, offloading between $60 million and $77 million in combined Robinhood and Roku positions while simultaneously deploying capital into Eli Lilly, Coinbase, and additional growth-oriented investments.
The timing aligned with positive news catalysts that had driven both exited stocks higher, providing ARK with an opportune moment to realize profits.
Through the ARK Innovation ETF, the firm disposed of 275,572 Robinhood shares valued at approximately $26.65 million. This divestment occurred immediately after Robinhood’s public disclosure of plans to eliminate roughly 10% of full-time positions—approximately 290 employees—as CEO Vlad Tenev emphasized organizational efficiency. The workforce reduction announcement triggered positive market response and prompted several analysts to raise their price targets.
Regarding Roku, ARK divested between 239,267 and 561,800 shares distributed across ARKK, ARKW, and ARKF funds, representing a total value ranging from $33 million to $77.57 million based on allocation specifics. This exit strategy followed Fox’s definitive agreement to acquire Roku through a $22 billion transaction at a fixed $160 per share price point, effectively establishing a near-term price ceiling. With acquisition terms locked in, additional upside potential became significantly limited.
Capital Redeployment Targets Eli Lilly and Coinbase
The realized gains were strategically redirected toward positions where ARK identified emerging opportunities.
Eli Lilly emerged as the primary beneficiary of this reallocation. ARK acquired 41,138 shares via its ARK Genomic Revolution ETF, representing approximately $46.18 million invested in the pharmaceutical giant following a recent stock decline. Lilly’s recent acquisition of 4E Therapeutics—a neuroscience firm developing non-opioid chronic pain therapies—expands its research pipeline beyond the company’s established obesity and diabetes medication portfolio.
Coinbase represented the second-largest purchase target. ARK accumulated 111,799 shares distributed across multiple funds, totaling roughly $18.92 million. The crypto exchange has been expanding its service offerings to include tokenized U.S. equities for international clients and AI-enhanced investment tools, transforming its business model from a pure cryptocurrency platform into a comprehensive financial services ecosystem.
Additional investments included $17.68 million allocated to Block shares, supplemented by smaller biotechnology sector positions.
SpaceX Secures Position Among Top Five Holdings
This portfolio adjustment occurred within a broader context of strategic positioning. Earlier that week, ARK had established a substantial post-IPO stake in SpaceX, acquiring nearly 3.3 million shares valued at approximately $531 million by the conclusion of its initial trading session.
Concurrently, Tesla CEO Elon Musk executed stock options according to a separate SEC disclosure, acquiring roughly 303.96 million shares at a $23.34 exercise price while relinquishing approximately 17.53 million shares to satisfy a $7.09 billion tax obligation. Musk’s current holdings stand at approximately 699.58 million shares, equating to a 19.9% voting interest in Tesla.
Tesla continues to represent ARK Innovation ETF’s largest allocation at 9.50%. Robinhood holds the second position at 4.93%, with CRISPR Therapeutics claiming 4.87%, Tempus AI at 4.83%, and SpaceX rounding out the top five at 4.71%.
These recent transactions indicate ARK’s deliberate strategy of exiting positions where immediate catalysts have materialized while reallocating resources toward opportunities with unrealized potential ahead.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
